Details of the Drug

General Information of Drug (ID: DMVR6OM)

Drug Name

Flotetuzumab

Indication

Disease Entry	ICD 11	Status	REF
Acute biphenotypic leukaemia	2B33.4	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 2	[2]
Myelodysplastic syndrome	2A37	Phase 1	[3]
------------------------------------------------------------------------------------

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acute biphenotypic leukaemia

ICD Disease Classification

2B33.4

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 3 receptor alpha (IL3RA)	DTT	IL3RA	8.71E-54	0.98	2.64

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03739606) Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)